This tells us what we know but in black and white from the company. In the SUVR greater than 2.5 group there was a statistically significant reduction in amyloid burden. In the less than 2.5 SUVR group there was not. It also showed a signal toward HA reduction (which we knew). IMO, we don't have all the data for other measures (ie. cognition etc), the placebo issues confounded the other measures and statistical measures between the treated and untreated groups.
AD PD 2015 Victor Villemagne's Abstract, page-2
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $3.631K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 60 | 81072032 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 2447647 | 3 |
View Market Depth
| Last trade - 15.59pm 18/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |